NASDAQ:DXCMDexCom Stock Price, Forecast & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DXCM stock has increased by 74.2% and is now trading at $439.64. View which stocks have been most impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DexCom.

DexCom is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for DexCom.

DexCom will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Tuesday, April, 28th. The medical device company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.29. The medical device company earned $405.10 million during the quarter, compared to the consensus estimate of $358.34 million. DexCom had a return on equity of 26.44% and a net margin of 9.24%. DexCom's revenue for the quarter was up 44.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.05) EPS. View DexCom's earnings history.

21 brokerages have issued 12-month target prices for DexCom's stock. Their forecasts range from $190.00 to $500.00. On average, they expect DexCom's stock price to reach $352.15 in the next twelve months. This suggests that the stock has a possible downside of 19.9%. View analysts' price targets for DexCom.

News stories about DXCM stock have been trending very negative on Monday, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DexCom earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about DexCom.

DexCom saw a decrease in short interest in June. As of June 30th, there was short interest totaling 4,400,000 shares, a decrease of 7.8% from the June 15th total of 4,770,000 shares. Based on an average daily trading volume, of 1,830,000 shares, the short-interest ratio is currently 2.4 days. Approximately 4.9% of the company's stock are short sold. View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), ServiceNow (NOW) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.01%), Acorn Financial Advisory Services Inc. ADV (0.00%), HNP Capital LLC (0.00%) and Paragon Advisors LLC (0.00%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Acorn Financial Advisory Services Inc. ADV. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli. View insider buying and selling activity for DexCom.

DXCM stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, HNP Capital LLC, Paragon Advisors LLC, Diversified Trust Co, Envestnet Asset Management Inc., Carnegie Capital Asset Management LLC, and Fulton Breakefield Broenniman LLC. View insider buying and selling activity for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $439.64.

DexCom has a market capitalization of $40.60 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]